BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treatment Reviews 2006;32:423-36. [DOI: 10.1016/j.ctrv.2006.05.005] [Cited by in Crossref: 383] [Cited by in F6Publishing: 356] [Article Influence: 23.9] [Reference Citation Analysis]
Number Citing Articles
1 Senta H, Park H, Bergeron E, Drevelle O, Fong D, Leblanc E, Cabana F, Roux S, Grenier G, Faucheux N. Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations. Cytokine & Growth Factor Reviews 2009;20:213-22. [DOI: 10.1016/j.cytogfr.2009.05.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 6.2] [Reference Citation Analysis]
2 Huang W, Deng H, Jin S, Ma X, Zha K, Xie M. The isolation, structural characterization and anti-osteosarcoma activity of a water soluble polysaccharide from Agrimonia pilosa. Carbohydrate Polymers 2018;187:19-25. [DOI: 10.1016/j.carbpol.2018.01.047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
3 Fan J, Yang X, Bi Z. 6-Gingerol inhibits osteosarcoma cell proliferation through apoptosis and AMPK activation. Tumor Biol 2015;36:1135-41. [DOI: 10.1007/s13277-014-2723-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
4 Bacci G, Balladelli A, Forni C, Ferrari S, Longhi A, Benassi M, Briccoli A, Serra M, Picci P. Adjuvant and neo-adjuvant chemotherapy for Ewing's sarcoma family tumors and osteosarcoma of the extremity: further outcome for patients event-free survivors 5 years from the beginning of treatment. Annals of Oncology 2007;18:2037-40. [DOI: 10.1093/annonc/mdm382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
5 Zhu XZ, Yin HM, Mei J. Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy. Acta Pharmacol Sin 2010;31:970-6. [PMID: 20686521 DOI: 10.1038/aps.2010.97] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan–dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009;30:3605-13. [DOI: 10.1016/j.biomaterials.2009.03.022] [Cited by in Crossref: 101] [Cited by in F6Publishing: 91] [Article Influence: 7.8] [Reference Citation Analysis]
7 Li X, Yan ML, Yu Q. Identification of candidate drugs for the treatment of metastatic osteosarcoma through a subpathway analysis method. Oncol Lett 2017;13:4378-84. [PMID: 28599440 DOI: 10.3892/ol.2017.5953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
8 Zhang C, Zhou H, Yuan K, Xie R, Chen C. Overexpression of hsa_circ_0136666 predicts poor prognosis and initiates osteosarcoma tumorigenesis through miR-593-3p/ZEB2 pathway. Aging (Albany NY) 2020;12:10488-96. [PMID: 32424109 DOI: 10.18632/aging.103273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
9 Kim HJ, Chalmers PN, Morris CD. Pediatric osteogenic sarcoma. Curr Opin Pediatr 2010;22:61-6. [PMID: 19915470 DOI: 10.1097/MOP.0b013e328334581f] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
10 Rettew AN, Young ED, Lev DC, Kleinerman ES, Abdul-Karim FW, Getty PJ, Greenfield EM. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 2012;1:e34. [PMID: 23552467 DOI: 10.1038/oncsis.2012.34] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
11 Wirries A, Jabari S, Jansen EP, Roth S, Figueroa-Juárez E, Wissniowski TT, Neureiter D, Klieser E, Lechler P, Ruchholtz S, Bartsch DK, Boese CK, Di Fazio P. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma. Oncotarget 2018;9:32997-3010. [PMID: 30250645 DOI: 10.18632/oncotarget.26038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
12 Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008;466:2168-75. [PMID: 18607665 DOI: 10.1007/s11999-008-0338-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
13 Foo LS, Hardes J, Henrichs M, Ahrens H, Gosheger G, Streitbürger A. Surgical difficulties encountered with use of modular endoprosthesis for limb preserving salvage of failed allograft reconstruction after malignant tumor resection. J Arthroplasty 2011;26:744-50. [PMID: 20692805 DOI: 10.1016/j.arth.2010.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
14 Udagawa T, Narumi K, Goto N, Aida K, Suzuki K, Ochiya T, Makimoto A, Yoshida T, Chikaraishi T, Aoki K. Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma. Hum Gene Ther 2012;23:173-86. [PMID: 21958207 DOI: 10.1089/hum.2011.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
15 de Nigris F, Zanella L, Cacciatore F, De Chiara A, Fazioli F, Chiappetta G, Apice G, Infante T, Monaco M, Rossiello R, De Rosa G, Alberghini M, Napoli C. YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma. BMC Cancer 2011;11:472. [PMID: 22047406 DOI: 10.1186/1471-2407-11-472] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
16 Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S, Sessa G. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Front Pharmacol 2017;8:150. [PMID: 28439237 DOI: 10.3389/fphar.2017.00150] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
17 Barani M, Mukhtar M, Rahdar A, Sargazi S, Pandey S, Kang M. Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma. Biosensors (Basel) 2021;11:55. [PMID: 33672770 DOI: 10.3390/bios11020055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
18 Zhou Z, Li Y, Jia Q, Wang Z, Wang X, Hu J, Xiao J. Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells. Cell Prolif 2017;50. [PMID: 28370690 DOI: 10.1111/cpr.12346] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
19 Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. Clin Orthop Relat Res 2008;466:1285-91. [PMID: 18421536 DOI: 10.1007/s11999-008-0243-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma Overview. Rheumatol Ther 2017;4:25-43. [PMID: 27933467 DOI: 10.1007/s40744-016-0050-2] [Cited by in Crossref: 146] [Cited by in F6Publishing: 148] [Article Influence: 24.3] [Reference Citation Analysis]
21 Hameed M, Dorfman H. Primary malignant bone tumors--recent developments. Semin Diagn Pathol 2011;28:86-101. [PMID: 21675380 DOI: 10.1053/j.semdp.2011.02.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
22 Zhang H, Wang G, Ding C, Liu P, Wang R, Ding W, Tong D, Wu D, Li C, Wei Q, Zhang X, Li D, Liu P, Cui H, Tang H, Ji F. Increased circular RNA UBAP2 acts as a sponge of miR-143 to promote osteosarcoma progression. Oncotarget 2017;8:61687-97. [PMID: 28977896 DOI: 10.18632/oncotarget.18671] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 17.8] [Reference Citation Analysis]
23 Bacci G, Ferrari S, Mercuri M, Longhi A, Fabbri N, Galletti S, Forni C, Balladelli A, Serra M, Picci P. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop 2007;78:377-84. [PMID: 17611853 DOI: 10.1080/17453670710013960] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
24 Tian W, Li Y, Zhang J, Li J, Gao J. Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures. Gene 2018;650:7-14. [PMID: 29407229 DOI: 10.1016/j.gene.2018.01.093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
25 Mateu-Sanz M, Tornín J, Brulin B, Khlyustova A, Ginebra MP, Layrolle P, Canal C. Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma. Cancers (Basel) 2020;12:E227. [PMID: 31963398 DOI: 10.3390/cancers12010227] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
26 Wu W, Dai Y, Liu H, Cheng R, Ni Q, Ye T, Cui W. Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma. Drug Deliv 2018;25:1642-51. [PMID: 30799654 DOI: 10.1080/10717544.2018.1497105] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
27 Wang Y, Shang G, Wang W, Qiu E, Pei Y, Zhang X. Magnoflorine inhibits the malignant phenotypes and increases cisplatin sensitivity of osteosarcoma cells via regulating miR-410-3p/HMGB1/NF-κB pathway. Life Sci 2020;256:117967. [PMID: 32553931 DOI: 10.1016/j.lfs.2020.117967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Kaste SC. Imaging pediatric bone sarcomas. Radiol Clin North Am 2011;49:749-65, vi-vii. [PMID: 21807172 DOI: 10.1016/j.rcl.2011.05.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
29 Chiu HW, Tseng YC, Hsu YH, Lin YF, Foo NP, Guo HR, Wang YJ. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. Cancer Lett 2015;356:762-72. [PMID: 25449439 DOI: 10.1016/j.canlet.2014.10.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
30 Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, Bacci G, Mercuri M. Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy 2014;11:217-27. [DOI: 10.1586/era.10.172] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
31 Yan G, Lv Y, Guo Q. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Letters 2016;370:268-74. [DOI: 10.1016/j.canlet.2015.11.003] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 15.3] [Reference Citation Analysis]
32 Kang HM, Park BS, Kang HK, Park HR, Yu SB, Kim IR. Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines. Environ Toxicol 2018;33:640-9. [PMID: 29451351 DOI: 10.1002/tox.22548] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
33 Bernardini G, Laschi M, Geminiani M, Santucci A. Proteomics of osteosarcoma. Expert Rev Proteomics 2014;11:331-43. [PMID: 24654989 DOI: 10.1586/14789450.2014.900445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
34 Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol. 2012;727:186-198. [PMID: 22399348 DOI: 10.1007/978-1-4614-0899-4_14] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 8.5] [Reference Citation Analysis]
35 Kataoka K, Ono T, Murata H, Morishita M, Yamamoto KI, Sakaguchi M, Huh NH. S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett 2012;3:1149-53. [PMID: 22783409 DOI: 10.3892/ol.2012.612] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
36 He C, Tang QX, Li YX, He K, Hou ZL. Effectiveness of electroacupuncture for pain after osteosarcoma post surgery: A study protocol of systematic review of randomized controlled trial. Medicine (Baltimore) 2019;98:e17381. [PMID: 31689744 DOI: 10.1097/MD.0000000000017381] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Gao X, Zhang C, Wang Y, Zhang P, Zhang J, Hong T. Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway. Molecules 2021;26:1666. [PMID: 33802664 DOI: 10.3390/molecules26061666] [Reference Citation Analysis]
38 Wang Y, Yang Z, Meng Z, Cao H, Zhu G, Liu T, Wang X. Knockdown of TRPM8 suppresses cancer malignancy and enhances epirubicin-induced apoptosis in human osteosarcoma cells. Int J Biol Sci 2013;10:90-102. [PMID: 24391455 DOI: 10.7150/ijbs.7738] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
39 Liu Q, Wang Z, Zhou X, Tang M, Tan W, Sun T, Deng Y. miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b. Cell Cycle 2019;18:3325-36. [PMID: 31601147 DOI: 10.1080/15384101.2019.1676087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
40 Andronescu E, Ficai A, Albu MG, Mitran V, Sonmez M, Ficai D, Ion R, Cimpean A. Collagen-hydroxyapatite/cisplatin drug delivery systems for locoregional treatment of bone cancer. Technol Cancer Res Treat 2013;12:275-84. [PMID: 23547973 DOI: 10.7785/tcrt.2012.500331] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
41 Muscella A, Stefàno E, De Bellis L, Nutricati E, Negro C, Marsigliante S. Antitumor and antimigration effects of Salvia clandestina L. extract on osteosarcoma cells. Ann N Y Acad Sci 2021. [PMID: 33960434 DOI: 10.1111/nyas.14601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Xu J, Xu G, Zhang T, Chen T, Zhao W, Wang G. NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression. Biomed Res Int 2019;2019:4068521. [PMID: 31886210 DOI: 10.1155/2019/4068521] [Reference Citation Analysis]
43 Liu SH, Zhu JW, Xu HH, Zhang GQ, Wang Y, Liu YM, Liang JB, Wang YX, Wu Y, Guo QF. A novel antisense long non-coding RNA SATB2-AS1 overexpresses in osteosarcoma and increases cell proliferation and growth. Mol Cell Biochem 2017;430:47-56. [PMID: 28190168 DOI: 10.1007/s11010-017-2953-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
44 Steinmann P, Walters DK, Arlt MJ, Banke IJ, Ziegler U, Langsam B, Arbiser J, Muff R, Born W, Fuchs B. Antimetastatic activity of honokiol in osteosarcoma. Cancer 2012;118:2117-27. [PMID: 21935912 DOI: 10.1002/cncr.26434] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
45 Batra H, Pawar S, Bahl D. Curcumin in combination with anti-cancer drugs: A nanomedicine review. Pharmacol Res 2019;139:91-105. [PMID: 30408575 DOI: 10.1016/j.phrs.2018.11.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 12.8] [Reference Citation Analysis]
46 Leng J, Song Q, Zhao Y, Wang Z. miR‑15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‑2 expression in human osteosarcoma cells. Int J Oncol 2018;52:1095-104. [PMID: 29484432 DOI: 10.3892/ijo.2018.4285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
47 Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008;21:231-7. [PMID: 18157089 DOI: 10.1038/modpathol.3800995] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 5.5] [Reference Citation Analysis]
48 Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. Cancer 2013;119:2645-53. [PMID: 23625626 DOI: 10.1002/cncr.28111] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
49 Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523-532. [PMID: 24345772 DOI: 10.1016/j.ctrv.2013.11.006] [Cited by in Crossref: 634] [Cited by in F6Publishing: 633] [Article Influence: 70.4] [Reference Citation Analysis]
50 Gill RK, Smith ZJ, Panchal RR, Bishop JW, Gandour-Edwards R, Wachsmann-Hogiu S. Preliminary fsLIBS study on bone tumors. Biomed Opt Express 2015;6:4850-8. [PMID: 26713199 DOI: 10.1364/BOE.6.004850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Sun Y, Liu L, Wang Y, He A, Hu H, Zhang J, Han M, Huang Y. Curcumin inhibits the proliferation and invasion of MG-63 cells through inactivation of the p-JAK2/p-STAT3 pathway. Onco Targets Ther 2019;12:2011-21. [PMID: 30936718 DOI: 10.2147/OTT.S172909] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
52 Liu P, Sun L, Zhou DS, Zhang P, Wang YH, Li D, Li QH, Feng RJ. Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma. Sci Rep 2015;5:17387. [PMID: 26619950 DOI: 10.1038/srep17387] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
53 Pierce TT, Shailam R, Lozano-Calderon S, Sagar P. Inter-rater Variability in the Interpretation of Pre and Post Contrast MRI for Pre-Surgical Evaluation of Osteosarcoma in Long Bones in Pediatric Patients and Young Adults. Surg Oncol 2019;28:135-9. [PMID: 30851887 DOI: 10.1016/j.suronc.2018.11.018] [Reference Citation Analysis]
54 Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012;2012:627254. [PMID: 22685381 DOI: 10.1155/2012/627254] [Cited by in Crossref: 110] [Cited by in F6Publishing: 97] [Article Influence: 11.0] [Reference Citation Analysis]
55 Errani C, Tsukamoto S, Mavrogenis AF. Imaging Analyses of Bone Tumors. JBJS Rev 2020;8:e0077. [PMID: 32149935 DOI: 10.2106/JBJS.RVW.19.00077] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
56 Fan J, Yang X, Bi Z. Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy. Tumour Biol 2014;35:9571-6. [PMID: 24961347 DOI: 10.1007/s13277-014-2156-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
57 Huang X, Liu J, Xie H. Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7. J Pharm Pharmacol 2021;73:720-5. [PMID: 33724400 DOI: 10.1093/jpp/rgab004] [Reference Citation Analysis]
58 Briccoli A, Rocca M, Salone M, Guzzardella GA, Balladelli A, Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: Long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surgical Oncology 2010;19:193-9. [DOI: 10.1016/j.suronc.2009.05.002] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 10.4] [Reference Citation Analysis]
59 Gao H, Guo Y, Zhang M, Yi Z. Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma. Biomed Res Int 2020;2020:6725753. [PMID: 32908905 DOI: 10.1155/2020/6725753] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Sakamoto A, Yamashita M, Hori Y, Okamoto T, Shimizu A, Matsuda S. Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis. Am J Case Rep 2017;18:1130-4. [PMID: 29061956 DOI: 10.12659/ajcr.905637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
61 Lee JA, Lim J, Jin HY, Park M, Park HJ, Park JW, Kim JH, Kang HG, Won YJ. Osteosarcoma in Adolescents and Young Adults. Cells 2021;10:2684. [PMID: 34685664 DOI: 10.3390/cells10102684] [Reference Citation Analysis]
62 Li G, Li Y, Wang DY. Overexpression of miR-329-3p sensitizes osteosarcoma cells to cisplatin through suppression of glucose metabolism by targeting LDHA. Cell Biol Int 2021;45:766-74. [PMID: 33058436 DOI: 10.1002/cbin.11476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Guan M, Wang J, Yang L, Zhao Z, Lu K, Zhao L, Xiao J, Li Z, Shi Z. Targeting osteosarcoma vasculature with peptide obtained by phage display. Contemp Oncol (Pozn) 2014;18:165-70. [PMID: 25520575 DOI: 10.5114/wo.2014.41384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Lee JW, Kim H, Kang HJ, Kim HS, Park SH, Kim IO, Ahn HS, Shin HY. Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation. Cancer Res Treat 2008;40:172-7. [PMID: 19688126 DOI: 10.4143/crt.2008.40.4.172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
65 Bartoloni A, Aparisi Gómez MP, Cirillo M, Allen G, Battista G, Guglielmi G, Tomà P, Bazzocchi A. Imaging of the limping child. Eur J Radiol 2018;109:155-70. [PMID: 30527299 DOI: 10.1016/j.ejrad.2018.10.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
66 Li C, Yu X, Guo D, Liu G, Zhang K, Teng Q, Lin H. Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis. Onco Targets Ther 2018;11:3495-504. [PMID: 29950854 DOI: 10.2147/OTT.S158167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kitajima H, Komizu Y, Ueoka R. Hybrid liposomes inhibit growth and invasion of human osteosarcoma cells leading to apoptosis. Bioorganic & Medicinal Chemistry Letters 2012;22:1784-7. [DOI: 10.1016/j.bmcl.2011.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
68 Wang J, Yuan L, Xu X, Zhang Z, Ma Y, Hong L, Ma J. Rho-GEF Trio regulates osteosarcoma progression and osteogenic differentiation through Rac1 and RhoA. Cell Death Dis 2021;12:1148. [PMID: 34893584 DOI: 10.1038/s41419-021-04448-3] [Reference Citation Analysis]
69 Lee JW, Kim KS, An HK, Kim CH, Moon HI, Lee YC. Dendropanoxide induces autophagy through ERK1/2 activation in MG-63 human osteosarcoma cells and autophagy inhibition enhances dendropanoxide-induced apoptosis. PLoS One 2013;8:e83611. [PMID: 24358301 DOI: 10.1371/journal.pone.0083611] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
70 Sollazzo V, Galasso M, Volinia S, Carinci F. Prion proteins (PRNP and PRND) are over-expressed in osteosarcoma. J Orthop Res 2012;30:1004-12. [PMID: 22147650 DOI: 10.1002/jor.22034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
71 Jiang R, Zhang C, Liu G, Gu R, Wu H. MicroRNA-107 Promotes Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Tropomyosin 1. Oncol Res 2017;25:1409-19. [PMID: 28276320 DOI: 10.3727/096504017X14882829077237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
72 Kimura R, Rokkaku T, Takeda S, Senba M, Mori N. Cytotoxic effects of fucoidan nanoparticles against osteosarcoma. Mar Drugs 2013;11:4267-78. [PMID: 24177673 DOI: 10.3390/md11114267] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
73 Wang B, Yu XC, Xu SF, Xu M. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnology 2015;13:22. [PMID: 25880868 DOI: 10.1186/s12951-015-0086-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 7.1] [Reference Citation Analysis]
74 Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, Wang Z, Wang Z, Cheng P, Tong D. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone. 2013;56:220-226. [PMID: 23756231 DOI: 10.1016/j.bone.2013.05.020] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 9.9] [Reference Citation Analysis]
75 Mavrogenis AF, Rossi G, Altimari G, Calabrò T, Angelini A, Palmerini E, Rimondi E, Ruggieri P. Palliative embolisation for advanced bone sarcomas. Radiol med 2013;118:1344-59. [DOI: 10.1007/s11547-012-0868-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
76 Gao AM, Yuan C, Hu AX, Liu XS. circ_ARF3 regulates the pathogenesis of osteosarcoma by sponging miR-1299 to maintain CDK6 expression. Cell Signal 2020;72:109622. [PMID: 32240746 DOI: 10.1016/j.cellsig.2020.109622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y, Huang SH. Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett 2012;4:878-82. [PMID: 23162615 DOI: 10.3892/ol.2012.862] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
78 Huang Y, Shen Z, Yao Y, He A, Min D. The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma. Onco Targets Ther 2021;14:213-20. [PMID: 33469302 DOI: 10.2147/OTT.S278139] [Reference Citation Analysis]
79 Daft PG, Yang Y, Napierala D, Zayzafoon M. The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism. PLoS One 2015;10:e0121568. [PMID: 25860662 DOI: 10.1371/journal.pone.0121568] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
80 Hattinger CM, Serra M. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. Expert Opin Drug Metab Toxicol 2015;11:1449-63. [PMID: 26095223 DOI: 10.1517/17425255.2015.1060220] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
81 Wootton-Gorges SL. MR imaging of primary bone tumors and tumor-like conditions in children. Magn Reson Imaging Clin N Am 2009;17:469-87, vi. [PMID: 19524197 DOI: 10.1016/j.mric.2009.03.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
82 Mohanna F, Slaibi A, Al-Shehabi Z, Mahfoud M. Osteosarcoma of the frontal bone: a study of a rare case in a 17-year-old female. J Surg Case Rep 2020;2020:rjaa138. [PMID: 32699592 DOI: 10.1093/jscr/rjaa138] [Reference Citation Analysis]
83 Umer M, Saeed J, Husseinali O. Malignant distal femur tumors management in children, low cost innovations with affordable care in a tertiary care hospital, a cross sectional study. Ann Med Surg (Lond) 2019;44:83-6. [PMID: 31341617 DOI: 10.1016/j.amsu.2019.07.012] [Reference Citation Analysis]
84 Fujita Y, Nakamura T, Aomori T, Nishiba H, Shinozaki T, Yanagawa T, Takagishi K, Watanabe H, Okada Y, Nakamura K, Horiuchi R, Yamamoto K. Pharmacokinetic Individualization of High-Dose Methotrexate Chemotherapy for the Treatment of localized Osteosarcoma. Journal of Chemotherapy 2013;22:186-90. [DOI: 10.1179/joc.2010.22.3.186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
85 Xu SH, Yang YL, Han SM, Wu ZH. MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma. World J Surg Oncol 2014;12:195. [PMID: 24969351 DOI: 10.1186/1477-7819-12-195] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
86 Morsy AM, Abdelgawad MI, Ahmed BM, Rezk KM, Aboelgheit AM, Ramadan IK, Kamel HEM, Fouad DM, Herdan RA, Shabaan SH, Eltyb HA. Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. J Pediatr Hematol Oncol 2019;41:e371-83. [PMID: 30629005 DOI: 10.1097/MPH.0000000000001407] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
87 Kiany S, Harrison D, Gordon N. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma. Adv Exp Med Biol 2020;1257:75-83. [PMID: 32483732 DOI: 10.1007/978-3-030-43032-0_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
88 Labrinidis A, Hay S, Liapis V, Findlay DM, Evdokiou A. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. Int J Cancer 2010;127:345-54. [PMID: 19924813 DOI: 10.1002/ijc.25051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
89 Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 2021. [PMID: 33408328 DOI: 10.1038/s41417-020-00281-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Ma W, Yang L, Liu H, Chen P, Ren H, Ren P. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma. Biochem Biophys Res Commun 2020;521:204-11. [PMID: 31640855 DOI: 10.1016/j.bbrc.2019.10.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
91 Cheng D, Li J, Zhang L, Hu L. miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway. Oncol Lett 2019;17:1363-71. [PMID: 30655907 DOI: 10.3892/ol.2018.9712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
92 Zhou R, Zhang Z, Zhao L, Jia C, Xu S, Mai Q, Lu M, Huang M, Wang L, Wang X, Jin D, Bai X. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells: OA INHIBITS mTOR IN OSTEOSARCOMA. J Orthop Res 2011;29:846-52. [DOI: 10.1002/jor.21311] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
93 Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N. Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion. PLoS One 2016;11:e0166500. [PMID: 27851822 DOI: 10.1371/journal.pone.0166500] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
94 Arlt MJ, Banke IJ, Walters DK, Puskas GJ, Steinmann P, Muff R, Born W, Fuchs B. LacZ transgene expression in the subcutaneous Dunn/LM8 osteosarcoma mouse model allows for the identification of micrometastasis: METASTASIS OF LACZ- TRANSGENIC DUNN/LM8 MOUSE OSTEOSARCOMA CELLS. J Orthop Res 2011;29:938-46. [DOI: 10.1002/jor.21304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
95 Liu W, Li T, Hu W, Ji Q, Hu F, Wang Q, Yang X, Qi D, Chen H, Zhang X. Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway. J Cell Mol Med 2021. [PMID: 34363435 DOI: 10.1111/jcmm.16836] [Reference Citation Analysis]
96 Han JA, Kim JY, Kim JI. Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines. Genomics Inform 2014;12:247-53. [PMID: 25705166 DOI: 10.5808/GI.2014.12.4.247] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
97 Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962-9. [PMID: 18483362 DOI: 10.1158/1078-0432.CCR-07-1992] [Cited by in Crossref: 114] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
98 Wang Q, Yu X, Li F, Lv X, Fu X, Gu H, Liu H, Liu J, Dai M, Zhang B. Efficacy of celastrol combined with cisplatin in enhancing the apoptosis of U-2OS osteosarcoma cells via the mitochondrial and endoplasmic reticulum pathways of apoptosis. Oncol Lett 2019;17:3305-13. [PMID: 30867764 DOI: 10.3892/ol.2019.10007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Guo H, Peng J, Hu J, Chang S, Liu H, Luo H, Chen X, Tang H, Chen Y. BAIAP2L2 promotes the proliferation, migration and invasion of osteosarcoma associated with the Wnt/β-catenin pathway. J Bone Oncol 2021;31:100393. [PMID: 34786330 DOI: 10.1016/j.jbo.2021.100393] [Reference Citation Analysis]
100 Kim CH, Lee JH, Lee JW, Kim E, Choi SH. Introducing a New Biomarker Named R2*-BOLD-MRI Parameter to Assess Treatment Response in Osteosarcoma. J Magn Reson Imaging 2021. [PMID: 34888987 DOI: 10.1002/jmri.28023] [Reference Citation Analysis]
101 Gvozdenovic A, Arlt MJ, Campanile C, Brennecke P, Husmann K, Li Y, Born W, Muff R, Fuchs B. CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 2013;28:838-47. [PMID: 23169460 DOI: 10.1002/jbmr.1817] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
102 Liu W, Liu SY, He YB, Huang RL, Deng SY, Ni GX, Yu B. MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor. Biomed Pharmacother 2017;87:621-7. [PMID: 28086136 DOI: 10.1016/j.biopha.2016.12.121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
103 Scionti I, Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 2008;19:1500-8. [PMID: 18385200 DOI: 10.1093/annonc/mdn148] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
104 Yang J, Zou Y, Jiang D. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells. Int J Mol Med 2018;41:1845-54. [PMID: 29393336 DOI: 10.3892/ijmm.2018.3433] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
105 Le Nail LR, Brennan M, Rosset P, Deschaseaux F, Piloquet P, Pichon O, Le Caignec C, Crenn V, Layrolle P, Hérault O, De Pinieux G, Trichet V. Comparison of Tumor- and Bone Marrow-Derived Mesenchymal Stromal/Stem Cells from Patients with High-Grade Osteosarcoma. Int J Mol Sci 2018;19:E707. [PMID: 29494553 DOI: 10.3390/ijms19030707] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
106 Berger M, Grignani G, Ferrari S, Biasin E, Brach del Prever A, Aliberti S, Saglio F, Aglietta M, Fagioli F. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009;115:2980-7. [PMID: 19452540 DOI: 10.1002/cncr.24368] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
107 Takagi-kimura M, Yamano T, Tagawa M, Kubo S. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses. Cancer Gene Ther 2014;21:126-32. [DOI: 10.1038/cgt.2014.7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
108 Sun C, Liu C, Dong J, Li D, Li W. Effects of the myeloid cell nuclear differentiation antigen on the proliferation, apoptosis and migration of osteosarcoma cells. Oncol Lett 2014;7:815-9. [PMID: 24520299 DOI: 10.3892/ol.2014.1811] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
109 Liu Q, Jiang L, Wang W, Jiang T. BTF3 Silencing Inhibits the Proliferation of Osteosarcoma Cells. J Cancer 2019;10:1855-61. [PMID: 31205542 DOI: 10.7150/jca.28476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Deel MD, Li JJ, Crose LE, Linardic CM. A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol 2015;5:190. [PMID: 26389076 DOI: 10.3389/fonc.2015.00190] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
111 De Luca A, Raimondi L, Salamanna F, Carina V, Costa V, Bellavia D, Alessandro R, Fini M, Giavaresi G. Relevance of 3d culture systems to study osteosarcoma environment. J Exp Clin Cancer Res 2018;37:2. [PMID: 29304852 DOI: 10.1186/s13046-017-0663-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
112 Liu W, Zhou Z, Zhang Q, Rong Y, Li L, Luo Y, Wang J, Yin G, Lv C, Cai W. Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma. Biochem Biophys Res Commun 2019;510:479-86. [PMID: 30737029 DOI: 10.1016/j.bbrc.2019.01.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
113 Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PFM. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. Journal of Microencapsulation 2008;25:421-5. [DOI: 10.1080/02652040802033673] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
114 Morii R, Tsukamoto S, Righi A, Honoki K, Tanaka Y, Kido A, Fujii H, Mavrogenis AF, Tanaka Y, Errani C. Effect of Adjuvant Chemotherapy on Localized Malignant Giant Cell Tumor of Bone: A Systematic Review. Cancers (Basel) 2021;13:5410. [PMID: 34771573 DOI: 10.3390/cancers13215410] [Reference Citation Analysis]
115 Hız M, Karaismailoglu B, Ulutas S, Camurdan VB, Gorgun B, Oner Dincbas F. The effect of preoperative radiotherapy on local control and prognosis in high-grade non-metastatic intramedullary osteosarcoma of the extremities. Arch Orthop Trauma Surg 2021;141:1083-9. [PMID: 32506177 DOI: 10.1007/s00402-020-03494-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
116 Dutour A, Decouvelaere A, Monteil J, Duclos M, Roualdes O, Rousseau R, Marec-bérard P. 18 F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model. J Nucl Med 2009;50:1533-40. [DOI: 10.2967/jnumed.109.062356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
117 Zhu J, Zou J, Zhang Z, Zhang J, Sun Y, Dong X, Zhang Q. An NIR triphenylamine grafted BODIPY derivative with high photothermal conversion efficiency and singlet oxygen generation for imaging guided phototherapy. Mater Chem Front 2019;3:1523-31. [DOI: 10.1039/c9qm00044e] [Cited by in Crossref: 23] [Article Influence: 7.7] [Reference Citation Analysis]
118 Shen S, Zhou M, Huang K, Wu Y, Ma Y, Wang J, Ma J, Fan S. Blocking autophagy enhances the apoptotic effect of 18β-glycyrrhetinic acid on human sarcoma cells via endoplasmic reticulum stress and JNK activation. Cell Death Dis 2017;8:e3055. [PMID: 28933787 DOI: 10.1038/cddis.2017.441] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
119 Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, Zhao J. mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2010;27:1239-45. [PMID: 19936974 DOI: 10.1007/s12032-009-9365-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
120 Mavrogenis AF, Rossi G, Rimondi E, Calabrò T, Papagelopoulos PJ, Ruggieri P. Palliative embolization for osteosarcoma. Eur J Orthop Surg Traumatol 2014;24:1351-6. [DOI: 10.1007/s00590-013-1312-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
121 Chen J, Jin X, Mei Y, Shen Z, Zhu J, Shi H, Wang M, Zheng X, Liang G. The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to G-quadruplex. Cell Prolif 2021;:e13101. [PMID: 34296479 DOI: 10.1111/cpr.13101] [Reference Citation Analysis]
122 Jin Z, Liu S, Zhu P, Tang M, Wang Y, Tian Y, Li D, Zhu X, Yan D, Zhu Z. Cross-Species Gene Expression Analysis Reveals Gene Modules Implicated in Human Osteosarcoma. Front Genet 2019;10:697. [PMID: 31440272 DOI: 10.3389/fgene.2019.00697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
123 Liu C, Ma M, Zhang J, Gui S, Zhang X, Xue S. Galangin inhibits human osteosarcoma cells growth by inducing transforming growth factor-β1-dependent osteogenic differentiation. Biomed Pharmacother 2017;89:1415-21. [PMID: 28340520 DOI: 10.1016/j.biopha.2017.03.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
124 Yang H, Peng Z, Liang M, Zhang Y, Wang Y, Huang T, Jiang Y, Jiang B, Wang Y. The miR-17-92 cluster/QKI2/β-catenin axis promotes osteosarcoma progression. Oncotarget 2018;9:25285-93. [PMID: 29861871 DOI: 10.18632/oncotarget.23935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
125 Liu S, Yi Z, Ling M, Shi J, Qiu Y, Yang S. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy. Tumour Biol 2014;35:9897-904. [PMID: 24996541 DOI: 10.1007/s13277-014-1917-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
126 Li J, Liu S, Wang W, Zhang K, Liu Z, Zhang C, Chen S, Wu S. ERCC polymorphisms and prognosis of patients with osteosarcoma. Tumour Biol 2014;35:10129-36. [PMID: 25023406 DOI: 10.1007/s13277-014-2322-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
127 Liu P, Liu W, Gao H, Zhang Y, Yan M, Wang X. Circ0085539 Promotes Osteosarcoma Progression by Suppressing miR-526b-5p and PHLDA1 Axis. Front Oncol 2020;10:1250. [PMID: 32983961 DOI: 10.3389/fonc.2020.01250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Zhou G, Lu M, Chen J, Li C, Zhang J, Chen J, Shi X, Wu S. Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma. Tumour Biol 2015;36:8845-52. [PMID: 26069101 DOI: 10.1007/s13277-015-3421-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
129 Xu E, Ji Z, Jiang H, Lin T, Ma J, Zhou X. Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis. Biomed Res Int 2019;2019:5630124. [PMID: 31930127 DOI: 10.1155/2019/5630124] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Wang Z, Mei J, Gao Y, Ni M, Yao B. Primary tumorectomy promotes angiogenesis and pulmonary metastasis in osteosarcoma-bearing nude mice. Acta Cir Bras 2013;28:190-4. [DOI: 10.1590/s0102-86502013000300006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
131 Scott SJ, Salgaonkar V, Prakash P, Burdette EC, Diederich CJ. Interstitial ultrasound ablation of vertebral and paraspinal tumours: parametric and patient-specific simulations. Int J Hyperthermia 2014;30:228-44. [PMID: 25017322 DOI: 10.3109/02656736.2014.915992] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
132 Zhou G, Shi X, Zhang J, Wu S, Zhao J. MicroRNAs in osteosarcoma: From biological players to clinical contributors, a review. J Int Med Res 2013;41:1-12. [DOI: 10.1177/0300060513475959] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
133 Chen J, Guo X, Zeng G, Liu J, Zhao B. Transcriptome Analysis Identifies Novel Prognostic Genes in Osteosarcoma. Comput Math Methods Med 2020;2020:8081973. [PMID: 33082842 DOI: 10.1155/2020/8081973] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Zhang MS, Niu FW, Li K. Proflavin suppresses the growth of human osteosarcoma MG63 cells through apoptosis and autophagy. Oncol Lett 2015;10:463-8. [PMID: 26171052 DOI: 10.3892/ol.2015.3206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
135 Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54. [PMID: 21385891 DOI: 10.1124/jpet.110.178400] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
136 Huang Y, Chen J, Yang S, Tan T, Wang N, Wang Y, Zhang L, Yang C, Huang H, Luo J, Luo X. Cinnamaldehyde Inhibits the Function of Osteosarcoma by Suppressing the Wnt/β-Catenin and PI3K/Akt Signaling Pathways. Drug Des Devel Ther 2020;14:4625-37. [PMID: 33154629 DOI: 10.2147/DDDT.S277160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Garimella R, Tadikonda P, Tawfik O, Gunewardena S, Rowe P, Van Veldhuizen P. Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells. Int J Mol Sci 2017;18:E642. [PMID: 28300755 DOI: 10.3390/ijms18030642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
138 Harada R, Kawamoto T, Ueha T, Minoda M, Toda M, Onishi Y, Fukase N, Hara H, Sakai Y, Miwa M, Kuroda R, Kurosaka M, Akisue T. Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells. Exp Cell Res 2013;319:1988-97. [PMID: 23727023 DOI: 10.1016/j.yexcr.2013.05.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
139 Huang W, Li D, Zheng Q, Li Q, Tao B. Osteosarcoma Cell Growth Inhibition by Isoxanthanol-Nanoparticles through Histone H3 Lysine 27 Trimethylation Downregulation and AMPK Activation. Dokl Biochem Biophys 2021;500:347-53. [PMID: 34697742 DOI: 10.1134/S1607672921050197] [Reference Citation Analysis]
140 Mickymaray S, Alfaiz FA, Paramasivam A, Veeraraghavan VP, Periadurai ND, Surapaneni KM, Niu G. Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway. Saudi J Biol Sci 2021;28:3641-9. [PMID: 34220214 DOI: 10.1016/j.sjbs.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, Amir G, Gebhardt M, Warman M, Stein GS, Stein JL, Lian JB, Aqeilan RI. Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res 2010;70:5577-86. [PMID: 20530675 DOI: 10.1158/0008-5472.CAN-09-4602] [Cited by in Crossref: 70] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
142 Hong Q, Fang J, Pang Y, Zheng J. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0037-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
143 Yu X, Zhou X, Fu C, Wang Q, Nie T, Zou F, Guo R, Liu H, Zhang B, Dai M. Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway. Oncol Rep 2015;34:1129-36. [PMID: 26165547 DOI: 10.3892/or.2015.4124] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
144 Wu X, Zhong D, Lin B, Zhai W, Ding Z, Wu J. p38 MAPK regulates the expression of ether à go-go potassium channel in human osteosarcoma cells. Radiol Oncol 2013;47:42-9. [PMID: 23450231 DOI: 10.2478/v10019-012-0043-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
145 Fan J, Zhou JQ, Yu GR, Lu DD. Glucose transporter protein 1-targeted RNA interference inhibits growth and invasion of the osteosarcoma cell line MG63 in vitro. Cancer Biother Radiopharm. 2010;25:521-527. [PMID: 20854211 DOI: 10.1089/cbr.2010.0784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
146 Zhao YL, Yang LB, Geng XL, Zhou QL, Qin H, Yang L, Dong YZ, Zhong JJ. The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma. Pak J Med Sci 2013;29:1225-9. [PMID: 24353725 DOI: 10.12669/pjms.295.3747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
147 Han X, Wang W, He J, Jiang L, Li X. Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett 2019;17:2592-8. [PMID: 30854034 DOI: 10.3892/ol.2019.9905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
148 Li H, Liu H, Pei J, Wang H, Lv H. miR‑542‑3p overexpression is associated with enhanced osteosarcoma cell proliferation and migration ability by targeting Van Gogh‑like 2. Mol Med Rep 2015;11:851-6. [PMID: 25352048 DOI: 10.3892/mmr.2014.2777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
149 Garcia-Moure M, Martinez-Vélez N, Patiño-García A, Alonso MM. Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope. J Bone Oncol 2017;9:41-7. [PMID: 29226089 DOI: 10.1016/j.jbo.2016.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
150 Li YY, Wu H, Dong YG, Lin BO, Xu G, Ma YB. Application of eupatilin in the treatment of osteosarcoma. Oncol Lett 2015;10:2505-10. [PMID: 26622880 DOI: 10.3892/ol.2015.3563] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
151 Messerschmitt PJ, Garcia RM, Thompson GH, Furey CG. Osteosarcoma of the spine causing vascular compression and pulmonary emboli on presentation. Current Orthopaedic Practice 2011;22:573-6. [DOI: 10.1097/bco.0b013e318225b845] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Gosavi AY, Puranik A, Agrawal A, Purandare N, Shah S. Dural Metastasis in Spinal Canal Diagnosed on F-18 Fluorodeoxyglucose Positron Emission Tomography Contrast-Enhanced Computed Tomography Scan in Treated Case of Osteogenic Sarcoma of the Left Femur. Indian J Nucl Med 2021;36:304-6. [PMID: 34658556 DOI: 10.4103/ijnm.ijnm_237_20] [Reference Citation Analysis]
153 Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P, Chen A, Huang H. The Fascinating Effects of Baicalein on Cancer: A Review. Int J Mol Sci 2016;17:E1681. [PMID: 27735841 DOI: 10.3390/ijms17101681] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 15.7] [Reference Citation Analysis]
154 Zhu K, Liu L, Zhang J, Wang Y, Liang H, Fan G, Jiang Z, Zhang CY, Chen X, Zhou G. MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6. Protein Cell 2016;7:434-44. [PMID: 27230400 DOI: 10.1007/s13238-016-0277-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
155 Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, Forni C, Briccoli A. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008;98:415-20. [PMID: 18792969 DOI: 10.1002/jso.21140] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 7.9] [Reference Citation Analysis]
156 Jiang B, Kang X, Zhao G, Lu J, Wang Z. miR-138 Reduces the Dysfunction of T Follicular Helper Cells in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1. Comput Math Methods Med 2021;2021:2895893. [PMID: 34950224 DOI: 10.1155/2021/2895893] [Reference Citation Analysis]
157 Bulut G, Hong SH, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee HS, Daar I, Toretsky JA, Khanna C, Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012;31:269-81. [PMID: 21706056 DOI: 10.1038/onc.2011.245] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 8.8] [Reference Citation Analysis]
158 Meng Z, Liu Y, Xu K, Sun X, Yu Q, Wu Z, Zhao Z. Biomimetic Polydopamine-Modified Silk Fibroin/Curcumin Nanofibrous Scaffolds for Chemo-photothermal Therapy of Bone Tumor. ACS Omega 2021;6:22213-23. [PMID: 34497912 DOI: 10.1021/acsomega.1c02903] [Reference Citation Analysis]
159 Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Mol Ther 2009;17:1651-7. [PMID: 19532136 DOI: 10.1038/mt.2009.126] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
160 Zhang J, Hou W, Chai M, Zhao H, Jia J, Sun X, Zhao B, Wang R. MicroRNA-127-3p inhibits proliferation and invasion by targeting SETD8 in human osteosarcoma cells. Biochem Biophys Res Commun 2016;469:1006-11. [PMID: 26707641 DOI: 10.1016/j.bbrc.2015.12.067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
161 Liu Z, Zhang G, Zhao C, Li J. Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma. Med Sci Monit 2018;24:5216-24. [PMID: 30052620 DOI: 10.12659/MSM.909555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
162 Wolf-Dennen K, Gordon N, Kleinerman ES. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. Oncoimmunology 2020;9:1747677. [PMID: 32313728 DOI: 10.1080/2162402X.2020.1747677] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
163 Zhao Q, Wang C, Zhu J, Wang L, Dong S, Zhang G, Tian J. RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control study. J Exp Clin Cancer Res 2011;30:26. [PMID: 21375766 DOI: 10.1186/1756-9966-30-26] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
164 Zhang L, Zhang L, Xia X, He S, He H, Zhao W. Krüppel-like factor 4 promotes human osteosarcoma growth and metastasis via regulating CRYAB expression. Oncotarget 2016;7:30990-1000. [PMID: 27105535 DOI: 10.18632/oncotarget.8824] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
165 Tan ML, Choong PF, Dass CR. Anti-Tumour Effect of a Chitosan Delivery System for Doxorubicin. AMR 2010;93-94:703-6. [DOI: 10.4028/www.scientific.net/amr.93-94.703] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Zheng M, Wu Y. Piceatannol suppresses proliferation and induces apoptosis by regulation of the microRNA‑21/phosphatase and tensin homolog/protein kinase B signaling pathway in osteosarcoma cells. Mol Med Rep 2020;22:3985-93. [PMID: 32901863 DOI: 10.3892/mmr.2020.11484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
167 Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009;28:247-63. [PMID: 19214708 DOI: 10.1007/s10555-009-9186-7] [Cited by in Crossref: 174] [Cited by in F6Publishing: 167] [Article Influence: 13.4] [Reference Citation Analysis]
168 Das S, Idate R, Regan DP, Fowles JS, Lana SE, Thamm DH, Gustafson DL, Duval DL. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. Commun Biol 2021;4:1178. [PMID: 34635775 DOI: 10.1038/s42003-021-02683-0] [Reference Citation Analysis]
169 Zhao X, Ma S, Liu N, Liu J, Wang W. A polysaccharide from Trametes robiniophila Murrill induces apoptosis through intrinsic mitochondrial pathway in human osteosarcoma (U-2 OS) cells. Tumor Biol 2015;36:5255-63. [DOI: 10.1007/s13277-015-3185-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
170 Ma C, Nie XG, Wang YL, Liu XH, Liang X, Zhou QL, Wu DP. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Mol Med Rep 2019;19:4205-12. [PMID: 30942427 DOI: 10.3892/mmr.2019.10104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
171 Zeng H, Zhang Z, Dai X, Chen Y, Ye J, Jin Z. Increased Expression of microRNA-199b-5p Associates with Poor Prognosis Through Promoting Cell Proliferation, Invasion and Migration Abilities of Human Osteosarcoma. Pathol Oncol Res 2016;22:253-60. [DOI: 10.1007/s12253-015-9901-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
172 Yang H, Li Y, Peng Z, Wang Y. Overexpression of miR-20a promotes the progression of osteosarcoma by directly targeting QKI2. Oncol Lett 2019;18:87-94. [PMID: 31289476 DOI: 10.3892/ol.2019.10313] [Reference Citation Analysis]
173 Masrouha KZ, Musallam KM, Samra AB, Tawil A, Haidar R, Chakhachiro Z, Saghieh S, Abdallah A, Saab R, Muwakkit S, Abboud MR, Khoury NJ. Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. Skeletal Radiol 2012;41:1453-61. [PMID: 22406919 DOI: 10.1007/s00256-012-1383-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
174 Pettke A, Hotfilder M, Clemens D, Klco-brosius S, Schaefer C, Potratz J, Dirksen U. Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. Anti-Cancer Drugs 2016;27:1001-10. [DOI: 10.1097/cad.0000000000000418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
175 Stitzlein RN, Wojcik J, Sebro RA, Balamuth NJ, Weber KL. Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents. JBJS Rev 2017;5:e5. [PMID: 29278618 DOI: 10.2106/JBJS.RVW.17.00030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
176 Yang J, Zhao L, Tian W, Liao Z, Zheng H, Wang G, Chen K. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genomics 2013;6:56. [PMID: 24330824 DOI: 10.1186/1755-8794-6-56] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
177 Ding FP, Tian JY, Wu J, Han DF, Zhao D. Identification of key genes as predictive biomarkers for osteosarcoma metastasis using translational bioinformatics. Cancer Cell Int 2021;21:640. [PMID: 34856991 DOI: 10.1186/s12935-021-02308-w] [Reference Citation Analysis]
178 Peng C, Hao Y, Ren Z, Zhu G, Yu L. Prognostic factors of chondroblastic osteosarcoma and nomogram development for prediction: A population-based, STROBE-compliant study. Medicine (Baltimore) 2021;100:e26021. [PMID: 34114989 DOI: 10.1097/MD.0000000000026021] [Reference Citation Analysis]
179 Yang Q, Chen T, Yao Z, Zhang X. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma. World J Surg Oncol 2020;18:24. [PMID: 32000789 DOI: 10.1186/s12957-020-1789-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
180 Messerschmitt PJ, Garcia RM, Abdul-karim FW, Greenfield EM, Getty PJ. Osteosarcoma: . Journal of the American Academy of Orthopaedic Surgeons 2009;17:515-27. [DOI: 10.5435/00124635-200908000-00005] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 11.7] [Reference Citation Analysis]
181 Hu H, Zhang Y, Cai XH, Huang JF, Cai L. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett 2012;4:1037-42. [PMID: 23162647 DOI: 10.3892/ol.2012.866] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
182 Palmerini E, Staals EL, Ferrari S, Rinaldi R, Alberghini M, Mercuri M, Bacci G. Nonresectable multiple lung metastases of high-grade osteosarcoma of the humerus: stable after twelve years. A case report. J Bone Joint Surg Am 2008;90:2240-4. [PMID: 18829923 DOI: 10.2106/JBJS.G.01619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
183 Zhang K, Tian F, Zhang Y, Zhu Q, Xue N, Zhu H, Wang H, Guo X. MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma. Tumour Biol 2014;35:2537-48. [PMID: 24163085 DOI: 10.1007/s13277-013-1335-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
184 Tu B, Du L, Fan QM, Tang Z, Tang TT. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 2012;325:80-8. [PMID: 22743617 DOI: 10.1016/j.canlet.2012.06.006] [Cited by in Crossref: 121] [Cited by in F6Publishing: 120] [Article Influence: 12.1] [Reference Citation Analysis]
185 Taniguchi M, Fujiwara K, Nakai Y, Ozaki T, Koshikawa N, Toshio K, Kataba M, Oguni A, Matsuda H, Yoshida Y, Tokuhashi Y, Fukuda N, Ueno T, Soma M, Nagase H. Inhibition of malignant phenotypes of human osteosarcoma cells by a gene silencer, a pyrrole-imidazole polyamide, which targets an E-box motif. FEBS Open Bio 2014;4:328-34. [PMID: 24918046 DOI: 10.1016/j.fob.2014.03.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
186 Ling Z, Fan G, Yao D, Zhao J, Zhou Y, Feng J, Zhou G, Chen Y. MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2. Exp Ther Med 2020;19:481-8. [PMID: 31897096 DOI: 10.3892/etm.2019.8231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
187 Errani C, Alfaro PA, Ponz V, Colangeli M, Donati DM, Manfrini M. Does the Addition of a Vascularized Fibula Improve the Results of a Massive Bone Allograft Alone for Intercalary Femur Reconstruction of Malignant Bone Tumors in Children? Clin Orthop Relat Res 2021;479:1296-308. [PMID: 33497066 DOI: 10.1097/CORR.0000000000001639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
188 Du L, Wang Y, Wang H, Cao J, Liu Q, Fan F. Knockdown of Rad51 expression induces radiation- and chemo-sensitivity in osteosarcoma cells. Med Oncol 2011;28:1481-7. [DOI: 10.1007/s12032-010-9605-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
189 Wang Z, Tan M, Chen G, Li Z, Lu X. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2: The Role of lnc RNA SOX2-OT in Osteosarcoma. IUBMB Life 2017;69:867-76. [DOI: 10.1002/iub.1681] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
190 Park H, Bergeron E, Senta H, Guillemette K, Beauvais S, Blouin R, Sirois J, Faucheux N. Sanguinarine induces apoptosis of human osteosarcoma cells through the extrinsic and intrinsic pathways. Biochem Biophys Res Commun. 2010;399:446-451. [PMID: 20678472 DOI: 10.1016/j.bbrc.2010.07.114] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
191 Xu T, Jiang W, Fan L, Gao Q, Li G. Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21. Oncotarget 2017;8:101406-17. [PMID: 29254174 DOI: 10.18632/oncotarget.20738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
192 Fujiwara T, Kawai A, Yoshida A, Ozaki T, Ochiya T. Cancer Stem Cells of Sarcoma. In: Zänker K, editor. Role of Cancer Stem Cells in Cancer Biology and Therapy. CRC Press; 2013. pp. 23-78. [DOI: 10.1201/b15734-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
193 Yuan Y, Song JX, Zhang MN, Yuan BS. A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma. Sci Rep 2020;10:15497. [PMID: 32968136 DOI: 10.1038/s41598-020-72552-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
194 Zhao L, Lv M, Sayimu W, Liu W, Zhang H, Jiang BO, Wang D. Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma. Oncol Lett 2015;10:879-82. [PMID: 26622587 DOI: 10.3892/ol.2015.3271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
195 Rasalkar DD, Chu WC, Lee V, Paunipagar BK, Cheng FW, Li CK. Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival. Pediatr Radiol 2011;41:227-36. [PMID: 20814672 DOI: 10.1007/s00247-010-1809-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
196 Wang LF, Zhou Y, Xu YM, Qiu XC, Zhou BG, Wang F, Long H, Chen X, Yang TT, Ma BA, Fan QY, Yang AG. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. Cancer Invest 2009;27:774-80. [PMID: 19488908 DOI: 10.1080/07357900802427935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
197 Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 2008;3:228-31. [PMID: 18782081 DOI: 10.2174/157488708785700267] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
198 Shi C, Zhang Z, Wang F, Luan Y. Active-targeting docetaxel-loaded mixed micelles for enhancing antitumor efficacy. Journal of Molecular Liquids 2018;264:172-8. [DOI: 10.1016/j.molliq.2018.05.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
199 Hou M, Huang Z, Chen S, Wang H, Feng T, Yan S, Su Y, Zuo G. Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells. Oncol Lett 2018;16:4663-70. [PMID: 30197679 DOI: 10.3892/ol.2018.9224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
200 Cortini M, Avnet S, Baldini N. Mesenchymal stroma: Role in osteosarcoma progression. Cancer Lett 2017;405:90-9. [PMID: 28774797 DOI: 10.1016/j.canlet.2017.07.024] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
201 Dass CR, Choong PFM. Non-viral methods for gene transfer towards osteosarcoma therapy. Journal of Drug Targeting 2008;15:184-9. [DOI: 10.1080/10611860701231547] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
202 Xiao X, Wang W, Wang Z. The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma. Pediatr Drugs 2014;16:503-12. [DOI: 10.1007/s40272-014-0095-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
203 Du GY, He SW, Zhang L, Sun CX, Mi LD, Sun ZG. Hesperidin exhibits in vitro and in vivo antitumor effects in human osteosarcoma MG-63 cells and xenograft mice models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosis. Oncol Lett 2018;16:6299-306. [PMID: 30405765 DOI: 10.3892/ol.2018.9439] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
204 Sahin Y, Altan Z, Arman K, Bozgeyik E, Koruk Ozer M, Arslan A. Inhibition of miR-664a interferes with the migration of osteosarcoma cells via modulation of MEG3. Biochemical and Biophysical Research Communications 2017;490:1100-5. [DOI: 10.1016/j.bbrc.2017.06.174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
205 Wu D, Wan M. Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo. Biomed Microdevices 2012;14:497-510. [DOI: 10.1007/s10544-011-9626-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
206 Cain JE, McCaw A, Jayasekara WS, Rossello FJ, Marini KD, Irving AT, Kansara M, Thomas DM, Ashley DM, Watkins DN. Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma 2013;2013:608964. [PMID: 23533324 DOI: 10.1155/2013/608964] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
207 Arlt MJ, Walters DK, Banke IJ, Steinmann P, Puskas GJ, Bertz J, Rentsch KM, Ehrensperger F, Born W, Fuchs B. The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer 2012;131:E804-12. [PMID: 22120774 DOI: 10.1002/ijc.27378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
208 Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y, Huang K, Wang G, Wang J, Ma J, Shen S, Fan S. Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. Mol Cancer 2019;18:73. [PMID: 30940151 DOI: 10.1186/s12943-019-1007-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 28.3] [Reference Citation Analysis]
209 Yong B, Tan P, Yin J, Zou C, Xie X, Wang J, Huang G, Wang Q, Shen J. Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma. World J Surg Oncol 2012;10:191. [PMID: 22985081 DOI: 10.1186/1477-7819-10-191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
210 Ficai D, Sonmez M, Albu MG, Mihaiescu DE, Ficai A, Bleotu C. Antitumoral materials with regenerative function obtained using a layer-by-layer technique. Drug Des Devel Ther 2015;9:1269-79. [PMID: 25767374 DOI: 10.2147/DDDT.S62805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
211 Zhao X, Ma S, Liu N, Liu J, Wang W. A polysaccharide from Trametes robiniophila inhibits human osteosarcoma xenograft tumor growth in vivo. Carbohydrate Polymers 2015;124:157-63. [DOI: 10.1016/j.carbpol.2015.02.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
212 Chan CD, Haagensen EJ, Tensaout HA, Rennie KJ, Gamie Z, Barry J, Birch MA, Gerrand CH, Nisar S, Robson CN, Lunec J, Rankin KS. Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia inducible factor-2α in osteosarcoma and prostate carcinoma cells. Oncol Lett 2021;21:158. [PMID: 33552276 DOI: 10.3892/ol.2020.12419] [Reference Citation Analysis]
213 Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Current and Emerging Targets in Immunotherapy for Osteosarcoma. J Oncol 2019;2019:7035045. [PMID: 30693030 DOI: 10.1155/2019/7035045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
214 Zwaga T, Bovée JV, Kroon HM. Osteosarcoma of the femur with skip, lymph node, and lung metastases. Radiographics 2008;28:277-83. [PMID: 18203943 DOI: 10.1148/rg.281075015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
215 Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M. The role of interferons in the treatment of osteosarcoma: Interferons and Osteosarcoma. Pediatr Blood Cancer 2010;54:350-4. [DOI: 10.1002/pbc.22136] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
216 Xiaohui S, Aiguo L, Xiaolin G, Ying L, Hongxing Z, Yilei Z. Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy. Pak J Med Sci 2014;30:886-90. [PMID: 25097538 DOI: 10.12669/pjms.304.4955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
217 Ouyang Y, Li H, Bu J, Li X, Chen Z, Xiao T. Hypoxia-inducible factor-1 expression predicts osteosarcoma patients' survival: a meta-analysis. Int J Biol Markers 2016;31:e229-34. [PMID: 27312586 DOI: 10.5301/jbm.5000216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
218 Xun C, Jiang D, Tian Z, Yunus A, Chen J. Long noncoding RNA plasmacytoma variant translocation gene 1 promotes epithelial-mesenchymal transition in osteosarcoma. J Clin Lab Anal 2021;35:e23587. [PMID: 32960485 DOI: 10.1002/jcla.23587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
219 Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 2009;30:4815-23. [DOI: 10.1016/j.biomaterials.2009.05.035] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
220 Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A. Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep 2016;6:39862. [PMID: 28008988 DOI: 10.1038/srep39862] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
221 Pu Y, Tan Y, Zang C, Zhao F, Cai C, Kong L, Deng H, Chao F, Xia R, Xie M, Ge F, Pan Y, Cai S, Huang D. LAMTOR5-AS1 regulates chemotherapy-induced oxidative stress by controlling the expression level and transcriptional activity of NRF2 in osteosarcoma cells. Cell Death Dis 2021;12:1125. [PMID: 34862368 DOI: 10.1038/s41419-021-04413-0] [Reference Citation Analysis]
222 Meazza C, Bastoni S, Scanagatta P. What is the best clinical approach to recurrent/refractory osteosarcoma? Expert Rev Anticancer Ther 2020;20:415-28. [PMID: 32379504 DOI: 10.1080/14737140.2020.1760848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
223 Zhao Y, Zhang C, Zeng B, Wu X, Gao T, Oda Y. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochemical and Biophysical Research Communications 2009;390:642-7. [DOI: 10.1016/j.bbrc.2009.10.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
224 Bian DL, Wang XM, Huang K, Zhai QX, Yu GB, Wu CH. Expression and regulatory effects of microRNA-182 in osteosarcoma cells: A pilot study. Oncol Lett 2016;11:3040-8. [PMID: 27123060 DOI: 10.3892/ol.2016.4375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
225 Zeng W, Liu Q, Chen Z, Wu X, Zhong Y, Wu J. Silencing of hERG1 Gene Inhibits Proliferation and Invasion, and Induces Apoptosis in Human Osteosarcoma Cells by Targeting the NF-κB Pathway. J Cancer 2016;7:746-57. [PMID: 27076857 DOI: 10.7150/jca.13289] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
226 Punzalan M, Hyden G. The role of physical therapy and occupational therapy in the rehabilitation of pediatric and adolescent patients with osteosarcoma. Cancer Treat Res 2009;152:367-84. [PMID: 20213402 DOI: 10.1007/978-1-4419-0284-9_20] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
227 Meazza C, Asaftei SD. State-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34058096 DOI: 10.1080/14656566.2021.1936499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Smolle MA, Andreou D, Tunn PU, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. EFORT Open Rev. 2017;2:421-431. [PMID: 29209518 DOI: 10.1302/2058-5241.2.170005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
229 Kumar H, Buch AC, Sawlani VM, Chandanwale SS. Diaphyseal osteosarcoma with varying histomorphologic patterns. Adv Biomed Res 2014;3:33. [PMID: 24600604 DOI: 10.4103/2277-9175.124685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Beltrami G, Ristori G, Nucci AM, Galeotti A, Tamburini A, Scoccianti G, Campanacci D, Innocenti M, Capanna R. Custom-Made 3D-Printed Implants as Novel Approach to Reconstructive Surgery after Oncologic Resection in Pediatric Patients. J Clin Med 2021;10:1056. [PMID: 33806387 DOI: 10.3390/jcm10051056] [Reference Citation Analysis]
231 Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 2011;20:13-9. [PMID: 19836228 DOI: 10.1016/j.suronc.2009.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
232 Kita K, Asanuma K, Okamoto T, Kawamoto E, Nakamura K, Hagi T, Nakamura T, Shimaoka M, Sudo A. Cytoskeletal Actin Structure in Osteosarcoma Cells Determines Metastatic Phenotype via Regulating Cell Stiffness, Migration, and Transmigration. Curr Issues Mol Biol 2021;43:1255-66. [PMID: 34698103 DOI: 10.3390/cimb43030089] [Reference Citation Analysis]
233 Jovičić MŠ, Vuletić F, Ribičić T, Šimunić S, Petrović T, Kolundžić R. Implementation of the three-dimensional printing technology in treatment of bone tumours: a case series. Int Orthop 2021;45:1079-85. [PMID: 32901331 DOI: 10.1007/s00264-020-04787-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Rudnick-Glick S, Corem-Salkmon E, Grinberg I, Margel S. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model. J Nanobiotechnology 2016;14:80. [PMID: 27919267 DOI: 10.1186/s12951-016-0233-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
235 Huh WW, Holsinger FC, Levy A, Palla FSL, Anderson PM. Osteosarcoma of the jaw in children and young adults. Head Neck 2012;34:981-4. [DOI: 10.1002/hed.21850] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
236 Sarigol-calamak E, Hascicek C. Tissue Scaffolds As a Local Drug Delivery System for Bone Regeneration. In: Chun HJ, Park CH, Kwon IK, Khang G, editors. Cutting-Edge Enabling Technologies for Regenerative Medicine. Singapore: Springer; 2018. pp. 475-93. [DOI: 10.1007/978-981-13-0950-2_25] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
237 Pu F, Chen F, Chen S, Wang B, Liu J, Shao Z. Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis. Onco Targets Ther 2015;8:1835-42. [PMID: 26229491 DOI: 10.2147/OTT.S81115] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
238 Li YS, Deng ZH, Zeng C, Lei GH. Role of osteopontin in osteosarcoma. Med Oncol 2015;32:449. [PMID: 25516504 DOI: 10.1007/s12032-014-0449-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
239 Hu C, Deng Z, Zhang Y, Yan L, Cai L, Lei J, Xie Y. The prognostic significance of Src and p-Src expression in patients with osteosarcoma. Med Sci Monit 2015;21:638-45. [PMID: 25725252 DOI: 10.12659/MSM.892803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
240 Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L, Scotlandi K. CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene 2014;33:1912-21. [PMID: 23644663 DOI: 10.1038/onc.2013.152] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
241 Zhang K, Zhang Y, Zhu H, Xue N, Liu J, Shan C, Zhu Q. High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumour Biol. 2014;35:1343-1350. [PMID: 24065195 DOI: 10.1007/s13277-013-1180-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
242 Koski C, Sarkar N, Bose S. Cytotoxic and osteogenic effects of crocin and bicarbonate from calcium phosphates for potential chemopreventative and anti-inflammatory applications in vitro and in vivo. J Mater Chem B 2020;8:2048-62. [PMID: 32064472 DOI: 10.1039/c9tb01462d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
243 Hashimoto K, Nishimura S, Oka N, Akagi M. Outcomes of comprehensive treatment for primary osteosarcoma. SAGE Open Med 2020;8:2050312120923177. [PMID: 32547749 DOI: 10.1177/2050312120923177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Huang Y, Liu B, Sun Y, Zhang J, Yao Y, He A. The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy. Oncotarget 2016;7:65568-76. [PMID: 27564105 DOI: 10.18632/oncotarget.11571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Li S, Xiong Y, Zhang X. Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma. Biomedicine & Pharmacotherapy 2017;90:872-9. [DOI: 10.1016/j.biopha.2017.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
246 Gurunathan S, Jeyaraj M, Kang MH, Kim JH. Tangeretin-Assisted Platinum Nanoparticles Enhance the Apoptotic Properties of Doxorubicin: Combination Therapy for Osteosarcoma Treatment. Nanomaterials (Basel) 2019;9:E1089. [PMID: 31362420 DOI: 10.3390/nano9081089] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
247 Di Pompo G, Cortini M, Palomba R, Di Francesco V, Bellotti E, Decuzzi P, Baldini N, Avnet S. Curcumin-Loaded Nanoparticles Impair the Pro-Tumor Activity of Acid-Stressed MSC in an In Vitro Model of Osteosarcoma. Int J Mol Sci 2021;22:5760. [PMID: 34071200 DOI: 10.3390/ijms22115760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Fan TM, Roberts RD, Lizardo MM. Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression. Front Oncol 2020;10:13. [PMID: 32082995 DOI: 10.3389/fonc.2020.00013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
249 Yang X, Zhou W, Liu S. SPAG9 controls the cell motility, invasion and angiogenesis of human osteosarcoma cells. Exp Ther Med 2016;11:637-44. [PMID: 26893659 DOI: 10.3892/etm.2015.2932] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
250 Lamego I, Duarte IF, Marques MP, Gil AM. Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin. J Proteome Res 2014;13:6033-45. [PMID: 25382592 DOI: 10.1021/pr500907d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
251 Wang Z, Wu B, Zhou Y, Huang X, Pan W, Liu M, Yan X, Lin N, Ye Z. Predictors of the Survival of Primary and Secondary Older Osteosarcoma Patients. J Cancer 2019;10:4614-22. [PMID: 31528225 DOI: 10.7150/jca.32627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
252 Lenna S, Bellotti C, Duchi S, Martella E, Columbaro M, Dozza B, Ballestri M, Guerrini A, Sotgiu G, Frisoni T, Cevolani L, Varchi G, Ferrari M, Donati DM, Lucarelli E. Mesenchymal stromal cells mediated delivery of photoactive nanoparticles inhibits osteosarcoma growth in vitro and in a murine in vivo ectopic model. J Exp Clin Cancer Res. 2020;39:40. [PMID: 32087737 DOI: 10.1186/s13046-020-01548-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
253 Zhang S, Zhao Y, Wang L. MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun 2016;472:557-65. [PMID: 26970302 DOI: 10.1016/j.bbrc.2016.03.040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
254 Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther 2016;3:221-43. [PMID: 27761754 DOI: 10.1007/s40744-016-0046-y] [Cited by in Crossref: 164] [Cited by in F6Publishing: 169] [Article Influence: 27.3] [Reference Citation Analysis]
255 Ashrafizadeh M, Rafiei H, Mohammadinejad R, Afshar EG, Farkhondeh T, Samarghandian S. Potential therapeutic effects of curcumin mediated by JAK/STAT signaling pathway: A review. Phytother Res 2020;34:1745-60. [PMID: 32157749 DOI: 10.1002/ptr.6642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
256 Reidy K, Campanile C, Muff R, Born W, Fuchs B. mTHPC-mediated photodynamic therapy is effective in the metastatic human 143B osteosarcoma cells. Photochem Photobiol 2012;88:721-7. [PMID: 22268498 DOI: 10.1111/j.1751-1097.2012.01096.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
257 Zhang Y, Sun S, Chen J, Ren P, Hu Y, Cao Z, Sun H, Ding Y. Oxymatrine induces mitochondria dependent apoptosis in human osteosarcoma MNNG/HOS cells through inhibition of PI3K/Akt pathway. Tumour Biol 2014;35:1619-25. [PMID: 24078465 DOI: 10.1007/s13277-013-1223-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
258 Sorenson B, Banton K, Augustin L, Barnett S, McCulloch K, Dorn J, Frykman N, Leonard A, Saltzman D. Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model. Biologics 2010;4:61-73. [PMID: 20376175 DOI: 10.2147/btt.s9121] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
259 Lv Z, Yang D, Li J, Hu M, Luo M, Zhan X, Song P, Liu C, Bai H, Li B, Yang Y, Chen Y, Shi Q, Weng Y. Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion. Mol Cells 2013;36:119-26. [PMID: 23807047 DOI: 10.1007/s10059-013-0043-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
260 Zhang D, Jiang F, Wang X, Li G. Knockdown of SALL4 Inhibits Proliferation, Migration, and Invasion in Osteosarcoma Cells. Oncol Res 2017;25:763-71. [PMID: 27983924 DOI: 10.3727/096504016X14772402056137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
261 Wang M, Wang L, Ren T, Xu L, Wen Z. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther 2013;14:155-63. [PMID: 23192273 DOI: 10.4161/cbt.22955] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
262 Kitajima H, Komizu Y, Ichihara H, Goto K, Ueoka R. Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells. Cancer Med 2013;2:267-76. [PMID: 23930203 DOI: 10.1002/cam4.67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
263 Tomsan H, Grady MF, Ganley TJ, Nguyen JC. Pediatric Elbow: Development, Common Pathologies, and Imaging Considerations. Semin Roentgenol 2021;56:245-65. [PMID: 34281678 DOI: 10.1053/j.ro.2021.05.007] [Reference Citation Analysis]
264 Manfrini M, Tiwari A, Ham J, Colangeli M, Mercuri M. Evolution of surgical treatment for sarcomas of proximal humerus in children: retrospective review at a single institute over 30 years. J Pediatr Orthop 2011;31:56-64. [PMID: 21150733 DOI: 10.1097/BPO.0b013e318202c223] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
265 Gindin Y, Jiang Y, Francis P, Walker RL, Abaan OD, Zhu YJ, Meltzer PS. miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1. Front Genet 2015;6:233. [PMID: 26191074 DOI: 10.3389/fgene.2015.00233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
266 Yin K, Liao Q, Zhong D, Ding J, Niu B, Long Q, Ding D. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. Exp Ther Med 2012;4:889-94. [PMID: 23226744 DOI: 10.3892/etm.2012.685] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
267 Xu L, Sun Z, Wei X, Tan H, Kong P, Li Z, Yang Q, Dai E, Li J. The inhibition of MARK2 suppresses cisplatin resistance of osteosarcoma stem cells by regulating DNA damage and repair. J Bone Oncol 2020;23:100290. [PMID: 32368441 DOI: 10.1016/j.jbo.2020.100290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
268 Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun. 2007;358:757-762. [PMID: 17506984 DOI: 10.1016/j.bbrc.2007.04.183] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
269 Wang H, Zhou JW, Fu DH, Zhou Y, Cheng WZ, Liu ZL. Gynura procumbens ethanolic extract suppresses osteosarcoma cell proliferation and metastasis in vitro.. Oncol Lett 2013;6:113-7. [PMID: 23946787 DOI: 10.3892/ol.2013.1315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
270 Huang G, Nishimoto K, Yang Y, Kleinerman ES. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Adv Exp Med Biol 2014;804:203-17. [PMID: 24924176 DOI: 10.1007/978-3-319-04843-7_11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
271 Presneau N, Duhamel LA, Ye H, Tirabosco R, Flanagan AM, Eskandarpour M. Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas. Br J Cancer 2017;117:398-408. [PMID: 28632727 DOI: 10.1038/bjc.2017.174] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
272 Klangjorhor J, Phanphaisarn A, Teeyakasem P, Chaiyawat P, Phinyo P, Settakorn J, Theera-Umpon N, Pruksakorn D. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients. Cancer Chemother Pharmacol 2020;85:1165-76. [PMID: 32476109 DOI: 10.1007/s00280-020-04081-5] [Reference Citation Analysis]
273 Zeitoun R, Shokry AM, Ahmed Khaleel S, Mogahed SM. Osteosarcoma subtypes: Magnetic resonance and quantitative diffusion weighted imaging criteria. J Egypt Natl Canc Inst 2018;30:39-44. [PMID: 29429892 DOI: 10.1016/j.jnci.2018.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
274 Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, Serra M. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs 2015;20:495-514. [PMID: 26021401 DOI: 10.1517/14728214.2015.1051965] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
275 Ek ETH, Dass CR, Contreras KG, Choong PFM. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007;14:616-26. [DOI: 10.1038/sj.cgt.7701044] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
276 Yang Z, Wa QD, Lu C, Pan W, Lu ZΜ, Ao J. miR‑328‑3p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX. Oncol Rep 2018;39:545-53. [PMID: 29207178 DOI: 10.3892/or.2017.6112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
277 Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Sharma N, Jeong DK. A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade. Dev Reprod 2014;18:197-212. [PMID: 25949190 DOI: 10.12717/devrep.2014.18.4.197] [Cited by in Crossref: 8] [Article Influence: 1.1] [Reference Citation Analysis]
278 Nie Z, Peng H. Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes. Oncol Lett 2018;16:6502-14. [PMID: 30405789 DOI: 10.3892/ol.2018.9453] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
279 Rhee SH, Han I, Lee MR, Cho HS, Oh JH, Kim HS. Role of integrin-linked kinase in osteosarcoma progression. J Orthop Res 2013;31:1668-75. [PMID: 23784942 DOI: 10.1002/jor.22409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
280 Mohamad O, Imai R, Kamada T, Nitta Y, Araki N; Working Group for Bone and Soft Tissue Sarcoma. Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget 2018;9:22976-85. [PMID: 29796166 DOI: 10.18632/oncotarget.25165] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
281 Lee JA, Kim MS, Kim DH, Lim JS, Yoo JY, Koh JS, Lee SY, Jeon DG, Park KD. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 2008;50:195-200. [PMID: 18061933 DOI: 10.1002/pbc.21446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
282 Zhang Y, Wei R, Zhu X, Cai L, Jin W, Hu H. Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anti-Cancer Drugs 2012;23:212-9. [DOI: 10.1097/cad.0b013e32834e5592] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
283 Chen JY, Kesavan, Sathiyamoorthy S, Tan MH. Atypical Presentation of High-Grade Intramedullary Osteosarcoma with Bilateral Cervical, Supraclavicular, and Axillary Lymphadenopathy: A Case Report and Literature Review. Proceedings of Singapore Healthcare 2013;22:277-83. [DOI: 10.1177/201010581302200408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
284 Pan F, Zhang J, Tang B, Jing L, Qiu B, Zha Z. The novel circ_0028171/miR-218-5p/IKBKB axis promotes osteosarcoma cancer progression. Cancer Cell Int 2020;20:484. [PMID: 33041665 DOI: 10.1186/s12935-020-01562-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
285 Liu Y, Guan J, Chen X. Identification of Differentially Expressed Genes under the Regulation of Transcription Factors in Osteosarcoma. Pathol Oncol Res 2019;25:1091-102. [PMID: 30411296 DOI: 10.1007/s12253-018-0519-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
286 Xiang H, Yang Q, Gao Y, Zhu D, Pan S, Xu T, Chen Y. Cocrystal Strategy toward Multifunctional 3D‐Printing Scaffolds Enables NIR‐Activated Photonic Osteosarcoma Hyperthermia and Enhanced Bone Defect Regeneration. Adv Funct Mater 2020;30:1909938. [DOI: 10.1002/adfm.201909938] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
287 Gao X, Li A, Zhang X, Liu P, Wang J, Cai X. Thyroid-stimulating hormone (TSH)-armed polymer–lipid nanoparticles for the targeted delivery of cisplatin in thyroid cancers: therapeutic efficacy evaluation. RSC Adv 2015;5:106413-20. [DOI: 10.1039/c5ra12588j] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
288 Ye B, Qiao K, Zhao Q, Jiang Z, Hu N, Wang F. Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis. Mol Cell Biochem 2021. [PMID: 34532813 DOI: 10.1007/s11010-021-04257-4] [Reference Citation Analysis]
289 Crompton JG, Ogura K, Bernthal NM, Kawai A, Eilber FC. Local Control of Soft Tissue and Bone Sarcomas. JCO 2018;36:111-7. [DOI: 10.1200/jco.2017.75.2717] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
290 Muñoz A, Alfaro J, Pardo N, García-Miguel P, Quintero V, Gros L, Melero C, Antuña MJ, Ocete G, de Las Heras J, Ruiz del Portal M, Huguet R, Maldonado MS. Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children. Clin Transl Oncol 2009;11:387-92. [PMID: 19531454 DOI: 10.1007/s12094-009-0373-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
291 Thompson L, Wang S, Tawfik O, Templeton K, Tancabelic J, Pinson D, Anderson HC, Keighley J, Garimella R. Effect of 25-hydroxyvitamin D3 and 1 α,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. J Orthop Res 2012;30:831-44. [PMID: 22042758 DOI: 10.1002/jor.21585] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
292 Goldman S, Echevarría ME, Fangusaro J. Pediatric Brain Metastasis from Extraneural Malignancies: A Review. In: Raizer JJ, Abrey LE, editors. Brain Metastases. Boston: Springer US; 2007. pp. 143-68. [DOI: 10.1007/978-0-387-69222-7_8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
293 Palmini G, Romagnoli C, Donati S, Zonefrati R, Galli G, Marini F, Iantomasi T, Aldinucci A, Leoncini G, Franchi A, Beltrami G, Campanacci DA, Capanna R, Brandi ML. Analysis of a Preliminary microRNA Expression Signature in a Human Telangiectatic Osteogenic Sarcoma Cancer Cell Line. Int J Mol Sci 2021;22:1163. [PMID: 33503899 DOI: 10.3390/ijms22031163] [Reference Citation Analysis]
294 Caronia D, Patiño-garcía A, Milne RL, Zalacain-díez M, Pita G, Alonso MR, Moreno LT, Sierrasesumaga-ariznabarreta L, Benítez J, González-neira A. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 2009;9:347-53. [DOI: 10.1038/tpj.2009.19] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
295 Wang Y, Chen J, Zhang D, Zhang Y, Wen Y, Li L, Zheng L. Tumoricidal effects of a selenium (Se)-polysaccharide from Ziyang green tea on human osteosarcoma U-2 OS cells. Carbohydrate Polymers 2013;98:1186-90. [DOI: 10.1016/j.carbpol.2013.07.022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
296 Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma 2011;2011:282745. [PMID: 21197465 DOI: 10.1155/2011/282745] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 6.4] [Reference Citation Analysis]
297 Raucci MG, Fasolino I, Caporali M, Serrano-Ruiz M, Soriente A, Peruzzini M, Ambrosio L. Exfoliated Black Phosphorus Promotes in Vitro Bone Regeneration and Suppresses Osteosarcoma Progression through Cancer-Related Inflammation Inhibition. ACS Appl Mater Interfaces 2019;11:9333-42. [PMID: 30758933 DOI: 10.1021/acsami.8b21592] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
298 Arnold L, Hendricks-Wenger A, Coutermarsh-Ott S, Gannon J, Hay AN, Dervisis N, Klahn S, Allen IC, Tuohy J, Vlaisavljevich E. Histotripsy Ablation of Bone Tumors: Feasibility Study in Excised Canine Osteosarcoma Tumors. Ultrasound Med Biol 2021;47:3435-46. [PMID: 34462159 DOI: 10.1016/j.ultrasmedbio.2021.08.004] [Reference Citation Analysis]
299 Jia D, Niu Y, Li D, Liu Z. lncRNA C2dat1 Promotes Cell Proliferation, Migration, and Invasion by Targeting miR-34a-5p in Osteosarcoma Cells. Oncol Res 2018;26:753-64. [PMID: 28810936 DOI: 10.3727/096504017X15024946480113] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
300 Novak RL, Phillips AC. Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis. Cancer Gene Ther 2008;15:713-22. [PMID: 18551146 DOI: 10.1038/cgt.2008.25] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
301 Avnet S, Lemma S, Cortini M, Di Pompo G, Perut F, Lipreri MV, Roncuzzi L, Columbaro M, Errani C, Longhi A, Zini N, Heymann D, Dominici M, Grisendi G, Golinelli G, Consolino L, Longo DL, Nanni C, Righi A, Baldini N. The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma. Cancers (Basel) 2021;13:5855. [PMID: 34831016 DOI: 10.3390/cancers13225855] [Reference Citation Analysis]
302 Lin CC, Chuang YJ, Yu CC, Yang JS, Lu CC, Chiang JH, Lin JP, Tang NY, Huang AC, Chung JG. Apigenin induces apoptosis through mitochondrial dysfunction in U-2 OS human osteosarcoma cells and inhibits osteosarcoma xenograft tumor growth in vivo. J Agric Food Chem 2012;60:11395-402. [PMID: 23066961 DOI: 10.1021/jf303446x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
303 Liu W, Zhao Z, Wang Y, Li W, Su Q, Jia Q, Zhang J, Zhang X, Shen J, Yin J. Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway. Cell Death Dis 2018;9:343. [PMID: 29497056 DOI: 10.1038/s41419-018-0363-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
304 Nguyenthai Q, Sharma N, Luong DH, Sodhi SS, Kim J, Kim N, Oh S, Jeong DK. Targeted inhibition of osteosarcoma tumor growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in tumor-bearing mice: Anti-tumor activity of CD/5FC-MSCs. J Gene Med 2015;17:87-99. [DOI: 10.1002/jgm.2826] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
305 Iram S, Zahera M, Wahid I, Baker A, Raish M, Khan A, Ali N, Ahmad S, Khan MS. Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence. Sci Rep 2019;9:13826. [PMID: 31554850 DOI: 10.1038/s41598-019-50215-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
306 Luu AK, Viloria-Petit AM. Targeting Mechanotransduction in Osteosarcoma: A Comparative Oncology Perspective. Int J Mol Sci 2020;21:E7595. [PMID: 33066583 DOI: 10.3390/ijms21207595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G, Gao Q. Lupeol Induces Apoptosis and Cell Cycle Arrest of Human Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway. Technol Cancer Res Treat 2016;15:NP16-24. [PMID: 26443801 DOI: 10.1177/1533034615609014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
308 Zhang N, Ying MD, Wu YP, Zhou ZH, Ye ZM, Li H, Lin DS. Hyperoside, a flavonoid compound, inhibits proliferation and stimulates osteogenic differentiation of human osteosarcoma cells. PLoS One 2014;9:e98973. [PMID: 24983940 DOI: 10.1371/journal.pone.0098973] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
309 Zhang H, He QY, Wang GC, Tong DK, Wang RK, Ding WB, Li C, Wei Q, Ding C, Liu PZ, Cui HC, Zhang X, Li D, Tang H, Ji F. miR-422a inhibits osteosarcoma proliferation by targeting BCL2L2 and KRAS. Biosci Rep 2018;38:BSR20170339. [PMID: 29358307 DOI: 10.1042/BSR20170339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
310 Akasbi Y, Arifi S, Lahlaidi K, Namad T, Mellas N, El Fassi MJ, Farih MH, Amarti A, El Mesbahi O. Renal metastases of a femur osteosarcoma: a case report and a review of the literature. Case Rep Urol 2012;2012:259193. [PMID: 22606633 DOI: 10.1155/2012/259193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
311 Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment. Br J Clin Pharmacol 2014;77:986-97. [PMID: 24134181 DOI: 10.1111/bcp.12260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
312 Yevich S, Gaspar N, Tselikas L, Brugières L, Pacquement H, Schleiermacher G, Tabone M, Pearson E, Canale S, Muret J, de Baere T, Deschamps F. Percutaneous Computed Tomography-Guided Thermal Ablation of Pulmonary Osteosarcoma Metastases in Children. Ann Surg Oncol 2016;23:1380-6. [DOI: 10.1245/s10434-015-4988-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
313 Liu Y, Sun X, Huo C, Sun C, Zhu J. Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma. Med Sci Monit 2019;25:4278-84. [PMID: 31177263 DOI: 10.12659/MSM.912272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
314 Palmini G, Zonefrati R, Mavilia C, Aldinucci A, Luzi E, Marini F, Franchi A, Capanna R, Tanini A, Brandi ML. Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma. J Vis Exp 2016. [PMID: 27768062 DOI: 10.3791/53884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
315 Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016;16:543-56. [PMID: 26999418 DOI: 10.1586/14737140.2016.1168697] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 15.2] [Reference Citation Analysis]
316 Li Y, Lim S, Ooi CP. Fabrication of Cisplatin-Loaded Poly(lactide-co-glycolide) Composite Microspheres for Osteosarcoma Treatment. Pharm Res 2012;29:756-69. [DOI: 10.1007/s11095-011-0600-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
317 An Y, Wang Y, Xu G, Liao Y, Huang G, Jin X, Xie C, Li Q, Yin D. Identification of key genes in osteosarcoma - before and after CDK7 treatment. Medicine (Baltimore) 2021;100:e27304. [PMID: 34596127 DOI: 10.1097/MD.0000000000027304] [Reference Citation Analysis]
318 Zhou W, Zhu Y, Chen S, Xu R, Wang K. Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma. Mol Med Rep 2016;13:713-9. [PMID: 26648125 DOI: 10.3892/mmr.2015.4597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
319 Shang G, Mi Y, Mei Y, Wang G, Wang Y, Li X, Wang Y, Li Y, Zhao G. MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11. Oncol Lett 2018;15:7265-72. [PMID: 29731885 DOI: 10.3892/ol.2018.8239] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
320 Hou J, Liu G, Zhang P, Wang B, Yan Q, Wu P, Wang C, Yao W. Experimental Study of Somatic Variants of Osteosarcoma by Whole-Exome Sequencing. Med Sci Monit 2020;26:e920826. [PMID: 32193367 DOI: 10.12659/MSM.920826] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
321 Picci P. Osteosarcoma: What did we learn from the paediatric experience for adolescents and young adults? European Journal of Cancer Supplements 2007;5:227-34. [DOI: 10.1016/s1359-6349(07)70044-7] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
322 Husmann K, Arlt MJ, Jirkof P, Arras M, Born W, Fuchs B. Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam. Lab Anim 2015;49:284-93. [PMID: 25650386 DOI: 10.1177/0023677215570989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
323 Oyewumi MO, Alazizi A, Wehrung D, Manochakian R, Safadi FF. Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol 2014;2014:236246. [PMID: 25197279 DOI: 10.1155/2014/236246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
324 Vijayamurugan N, Bakhshi S. Review of management issues in relapsed osteosarcoma. Expert Rev Anticancer Ther 2014;14:151-61. [PMID: 24308680 DOI: 10.1586/14737140.2014.863453] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
325 Capobianco E, Mora A, La Sala D, Roberti A, Zaki N, Badidi E, Taranta M, Cinti C. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One 2014;9:e95596. [PMID: 24756038 DOI: 10.1371/journal.pone.0095596] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
326 Li Y, Yu H, Sun H, Liu J, Tang Z, Wang D, Yu L, Chen X. Cisplatin-loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) nanoparticles as a potential chemotherapeutic agent against osteosarcoma. Chin J Polym Sci 2015;33:763-71. [DOI: 10.1007/s10118-015-1624-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
327 Yao W, Wang X, Cai Q, Gao S, Wang J, Zhang P. TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway. Oncol Res 2014;22:21-8. [PMID: 25700355 DOI: 10.3727/096504014X14077751730351] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
328 Spreafico A, Schenone S, Serchi T, Orlandini M, Angelucci A, Magrini D, Bernardini G, Collodel G, Di Stefano A, Tintori C, Bologna M, Manetti F, Botta M, Santucci A. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008;22:1560-71. [PMID: 18171692 DOI: 10.1096/fj.07-9873com] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
329 Salah Z, Arafeh R, Maximov V, Galasso M, Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM, Aqeilan RI. miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells. Oncotarget 2015;6:4920-35. [PMID: 25749032 DOI: 10.18632/oncotarget.3025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
330 Brosa M, García del Muro X, Mora J, Villacampa A, Pozo-rubio T, Cubells L, Montoto C. Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Review of Pharmacoeconomics & Outcomes Research 2015;15:331-40. [DOI: 10.1586/14737167.2015.972378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
331 Cho Y, Jung GH, Chung SH, Kim JY, Choi Y, Kim JD. Long-term survivals of stage IIb osteosarcoma: a 20-year experience in a single institution. Clin Orthop Surg 2011;3:48-54. [PMID: 21369478 DOI: 10.4055/cios.2011.3.1.48] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
332 Xie C, Chen B, Wu B, Guo J, Shi Y, Cao Y. CircSAMD4A regulates cell progression and epithelial‑mesenchymal transition by sponging miR‑342‑3p via the regulation of FZD7 expression in osteosarcoma. Int J Mol Med 2020;46:107-18. [PMID: 32319545 DOI: 10.3892/ijmm.2020.4585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Papachristou DJ, Papavassiliou AG. Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol 2007;39:857-62. [PMID: 17241811 DOI: 10.1016/j.biocel.2006.12.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
334 Dos Santos Cavalcanti A, Meohas W, Ribeiro GO, de Sá Lopes AC, Gholamin S, Razavi M, Hanae Kasai Brunswick T, Avan A, Matheus Guimarães JA, Leite Duarte ME, Kahn SA. Patient-derived osteosarcoma cells are resistant to methotrexate. PLoS One 2017;12:e0184891. [PMID: 28934267 DOI: 10.1371/journal.pone.0184891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
335 Lin H, Hao Y, Wan X, He J, Tong Y. Baicalein inhibits cell development, metastasis and EMT and induces apoptosis by regulating ERK signaling pathway in osteosarcoma. J Recept Signal Transduct Res 2020;40:49-57. [PMID: 31948366 DOI: 10.1080/10799893.2020.1713807] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
336 Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Sharma N, Jeong DK. A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade. Dev Reprod 2014;18:197-212. [PMID: 25949190 DOI: 10.12717/devrep.2014.18.4.197] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
337 Fan J, Mei J, Zhang MZ, Yuan F, Li SZ, Yu GR, Chen LH, Tang Q, Xian CJ. Clinicopathological significance of glucose transporter protein-1 overexpression in human osteosarcoma. Oncol Lett 2017;14:2439-45. [PMID: 28781680 DOI: 10.3892/ol.2017.6437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
338 Shapovalov Y, Benavidez D, Zuch D, Eliseev RA. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 2010;127:67-76. [PMID: 19894220 DOI: 10.1002/ijc.25024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
339 Wang X, Yu Y, Zang L, Zhang P, Ma J, Chen D. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells. CPB 2020;21:131-9. [DOI: 10.2174/1389201020666190821151120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
340 Shen Y, Hung G, Yen H, Hsieh M, Hsieh T. Early Development of Acute Myeloid Leukemia Following Treatment of Osteosarcoma: A Case Report and Review of the Literature. Pediatrics & Neonatology 2009;50:239-44. [DOI: 10.1016/s1875-9572(09)60070-x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
341 Johal S, Ralston S, Knight C. Mifamurtide for High-Grade, Resectable, Nonmetastatic Osteosarcoma Following Surgical Resection: A Cost-Effectiveness Analysis. Value in Health 2013;16:1123-32. [DOI: 10.1016/j.jval.2013.08.2294] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
342 Gao YS, Mei J, Tong TL, Hu M, Xue HM, Cai XS. Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother Radiopharm 2009;24:243-7. [PMID: 19409047 DOI: 10.1089/cbr.2008.0544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
343 Zhang H, Wang Y, Xu T, Li C, Wu J, He Q, Wang G, Ding C, Liu K, Tang H, Ji F. Increased expression of microRNA-148a in osteosarcoma promotes cancer cell growth by targeting PTEN. Oncol Lett 2016;12:3208-14. [PMID: 27899984 DOI: 10.3892/ol.2016.5050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
344 Farcas N, Arzi B, Verstraete FJM. Oral and maxillofacial osteosarcoma in dogs: a review: Canine oral osteosarcoma. Vet Comp Oncol 2014;12:169-80. [DOI: 10.1111/j.1476-5829.2012.00352.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
345 Ai J, Liao W, Ren Z. Enhanced anticancer effect of copper-loaded chitosan nanoparticles against osteosarcoma. RSC Adv 2017;7:15971-7. [DOI: 10.1039/c6ra21648j] [Cited by in Crossref: 17] [Article Influence: 3.4] [Reference Citation Analysis]
346 Hughes DP. Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv 2009;6:1311-21. [PMID: 19761419 DOI: 10.1517/17425240903280422] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
347 Salunke AA, Chen Y, Tan JH, Chen X, Khin LW, Puhaindran ME. Does a pathological fracture affect the prognosis in patients with osteosarcoma of the extremities?: A systematic review and meta-analysis. The Bone & Joint Journal 2014;96-B:1396-403. [DOI: 10.1302/0301-620x.96b10.34370] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
348 Sun HH, Chen XY, Cui JQ, Zhou ZM, Guo KJ. Prognostic factors to survival of patients with chondroblastic osteosarcoma. Medicine (Baltimore) 2018;97:e12636. [PMID: 30278586 DOI: 10.1097/MD.0000000000012636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
349 Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 2011;17:RA177-190. [PMID: 21804475 DOI: 10.12659/msm.881893] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
350 Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010;5:78. [PMID: 20979639 DOI: 10.1186/1749-799X-5-78] [Cited by in Crossref: 114] [Cited by in F6Publishing: 71] [Article Influence: 9.5] [Reference Citation Analysis]
351 Li L, Xu C, Liu P, Huang J. Correlation study of DNA methylation of WNT6 gene with osteosarcoma in children. Oncol Lett 2017;14:271-5. [PMID: 28693164 DOI: 10.3892/ol.2017.6135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
352 Rivera-Valentin RK, Zhu L, Hughes DP. Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015;17:257-71. [PMID: 26002157 DOI: 10.1007/s40272-015-0134-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
353 Ando K, Mori K, Verrecchia F, Marc B, Rédini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma 2012;2012:523432. [PMID: 22448123 DOI: 10.1155/2012/523432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
354 Zhang X, Hu Z, Li W, Liu Z, Li J, Wang Z, Martin VT, Yan B, Yu B. Circular RNA 0102049 suppresses the progression of osteosarcoma through modulating miR-520g-3p/PLK2 axis. Bioengineered 2021;12:2022-32. [PMID: 34060415 DOI: 10.1080/21655979.2021.1923259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
355 He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014;7:1352-62. [PMID: 24765137 DOI: 10.3892/ol.2014.1935] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 17.5] [Reference Citation Analysis]
356 Nada OH, Ahmed NS, Abou Gabal HH. Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 2014;9:72. [PMID: 24667142 DOI: 10.1186/1746-1596-9-72] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
357 Meazza C, Luksch R, Luzzati A. Managing axial bone sarcomas in childhood. Expert Rev Anticancer Ther 2021;21:747-64. [PMID: 33593222 DOI: 10.1080/14737140.2021.1891886] [Reference Citation Analysis]
358 Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH. The Current and Future Therapies for Human Osteosarcoma. Curr Cancer Ther Rev 2013;9:55-77. [PMID: 26834515 DOI: 10.2174/1573394711309010006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
359 Lu Y, Sun Y, Zhu J, Yu L, Jiang X, Zhang J, Dong X, Ma B, Zhang Q. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway. Cell Death Dis 2018;9:15. [PMID: 29323103 DOI: 10.1038/s41419-017-0031-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
360 Zhang Y, Xu H, Dai J. MiR-193b enhanced proliferation and migration and inhibits apoptosis through targeting RAB7A in osteosarcoma cell. Mol Cell Toxicol 2021;17:69-78. [DOI: 10.1007/s13273-020-00111-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Wang L, Wang W, Rui Z, Zhou D. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system. Drug Delivery 2016;23:3200-8. [DOI: 10.3109/10717544.2016.1162875] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
362 Errani C, Ceruso M, Donati DM, Manfrini M. Microsurgical reconstruction with vascularized fibula and massive bone allograft for bone tumors. Eur J Orthop Surg Traumatol 2019;29:307-11. [PMID: 30519732 DOI: 10.1007/s00590-018-2360-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
363 Mannerström B, Kornilov R, Abu-Shahba AG, Chowdhury IM, Sinha S, Seppänen-Kaijansinkko R, Kaur S. Epigenetic alterations in mesenchymal stem cells by osteosarcoma-derived extracellular vesicles. Epigenetics 2019;14:352-64. [PMID: 30907225 DOI: 10.1080/15592294.2019.1585177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
364 Kubohara Y, Komachi M, Homma Y, Kikuchi H, Oshima Y. Derivatives of Dictyostelium differentiation-inducing factors inhibit lysophosphatidic acid-stimulated migration of murine osteosarcoma LM8 cells. Biochem Biophys Res Commun 2015;463:800-5. [PMID: 26056940 DOI: 10.1016/j.bbrc.2015.06.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
365 Suri M, Soni N, Okpaleke N, Yadav S, Shah S, Iqbal Z, Alharbi MG, Kalra HS, Hamid P. A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review. Cureus 2021;13:e18349. [PMID: 34725602 DOI: 10.7759/cureus.18349] [Reference Citation Analysis]
366 Oh JY, Lee YJ, Kim EH. Tumor-Treating Fields Inhibit the Metastatic Potential of Osteosarcoma Cells. Technol Cancer Res Treat 2020;19:1533033820947481. [PMID: 32938326 DOI: 10.1177/1533033820947481] [Reference Citation Analysis]
367 Gonçalves C, Martins-neves SR, Paiva-oliveira D, Oliveira VE, Fontes-ribeiro C, Gomes CM. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins. Life Sciences 2015;130:47-56. [DOI: 10.1016/j.lfs.2015.03.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
368 Li S, Cheng D, Zhu B, Yang Q. The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3β/β-Catenin/cyclinD1 Signaling Pathway. Int J Biol Sci 2017;13:976-84. [PMID: 28924379 DOI: 10.7150/ijbs.19191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
369 Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 2010;10:819-832. [PMID: 20384524 DOI: 10.1517/14712598.2010.481666] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
370 Sun K, Wang J, Zhang J, Hua M, Liu C, Chen T. Dextran–g–PEI nanoparticles as a carrier for co-delivery of adriamycin and plasmid into osteosarcoma cells. International Journal of Biological Macromolecules 2011;49:173-80. [DOI: 10.1016/j.ijbiomac.2011.04.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
371 Sun L, Zhou D, Zhang P, Li Q, Liu P. RETRACTED: Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. International Journal of Pharmaceutics 2015;478:308-17. [DOI: 10.1016/j.ijpharm.2014.11.052] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
372 Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE. Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer 2015;113:1282-8. [PMID: 26461056 DOI: 10.1038/bjc.2015.351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
373 Terlecki RP, Triest JA, Madan SK, Vaishampayan UN. Nephrectomy in the Management of Metastatic Osteosarcoma. Clinical Genitourinary Cancer 2008;6:124-7. [DOI: 10.3816/cgc.2008.n.020] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
374 Teng JW, Yang ZM, Li J, Xu B. Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy. Pak J Med Sci 2013;29:1182-6. [PMID: 24353716 DOI: 10.12669/pjms.295.3870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
375 Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. Transl Oncol 2019;12:1257-63. [PMID: 31299622 DOI: 10.1016/j.tranon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
376 Voskuil RT, Miles DT, Scharschmidt TJ, Alexander JH. Noninvasive Expandable Endoprostheses From Reconstruction to Skeletal Maturity: A Surgical Technique and Lengthening Guide. J Am Acad Orthop Surg 2021;29:998-1007. [PMID: 34543240 DOI: 10.5435/JAAOS-D-21-00183] [Reference Citation Analysis]